222 related articles for article (PubMed ID: 12939285)
21. Fingolimod and Teriflunomide Attenuate Neurodegeneration in Mouse Models of Neuronal Ceroid Lipofuscinosis.
Groh J; Berve K; Martini R
Mol Ther; 2017 Aug; 25(8):1889-1899. PubMed ID: 28506594
[TBL] [Abstract][Full Text] [Related]
22. Coding sequence and exon/intron organization of the canine CLN3 (Batten disease) gene and its exclusion as the locus for ceroid-lipofuscinosis in English setter dogs.
Shibuya H; Liu PC; Katz ML; Siakotos AN; Nonneman DJ; Johnson GS
J Neurosci Res; 1998 May; 52(3):268-75. PubMed ID: 9590435
[TBL] [Abstract][Full Text] [Related]
23. Finding the most appropriate mouse model of juvenile CLN3 (Batten) disease for therapeutic studies: the importance of genetic background and gender.
Kovács AD; Pearce DA
Dis Model Mech; 2015 Apr; 8(4):351-61. PubMed ID: 26035843
[TBL] [Abstract][Full Text] [Related]
24. Cerebellar defects in a mouse model of juvenile neuronal ceroid lipofuscinosis.
Weimer JM; Benedict JW; Getty AL; Pontikis CC; Lim MJ; Cooper JD; Pearce DA
Brain Res; 2009 Apr; 1266():93-107. PubMed ID: 19230832
[TBL] [Abstract][Full Text] [Related]
25. Ocular morphology and function in juvenile neuronal ceroid lipofuscinosis (CLN3) in the first decade of life.
Preising MN; Abura M; Jäger M; Wassill KH; Lorenz B
Ophthalmic Genet; 2017; 38(3):252-259. PubMed ID: 27486012
[TBL] [Abstract][Full Text] [Related]
26. High resolution MRI reveals global changes in brains of Cln3 mutant mice.
Greene ND; Lythgoe MF; Thomas DL; Nussbaum RL; Bernard DJ; Mitchison HM
Eur J Paediatr Neurol; 2001; 5 Suppl A():103-7. PubMed ID: 11588978
[TBL] [Abstract][Full Text] [Related]
27. Altered arginine metabolism in the central nervous system (CNS) of the Cln3-/- mouse model of juvenile Batten disease.
Chan CH; Ramirez-Montealegre D; Pearce DA
Neuropathol Appl Neurobiol; 2009 Apr; 35(2):189-207. PubMed ID: 19284480
[TBL] [Abstract][Full Text] [Related]
28. Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten Mouse Model Consortium [corrected].
Mitchison HM; Bernard DJ; Greene ND; Cooper JD; Junaid MA; Pullarkat RK; de Vos N; Breuning MH; Owens JW; Mobley WC; Gardiner RM; Lake BD; Taschner PE; Nussbaum RL
Neurobiol Dis; 1999 Oct; 6(5):321-34. PubMed ID: 10527801
[TBL] [Abstract][Full Text] [Related]
29. Developmental impairments of select neurotransmitter systems in brains of Cln3(Deltaex7/8) knock-in mice, an animal model of juvenile neuronal ceroid lipofuscinosis.
Herrmann P; Druckrey-Fiskaaen C; Kouznetsova E; Heinitz K; Bigl M; Cotman SL; Schliebs R
J Neurosci Res; 2008 Jun; 86(8):1857-70. PubMed ID: 18265413
[TBL] [Abstract][Full Text] [Related]
30. A novel c.1135_1138delCTGT mutation in CLN3 leads to juvenile neuronal ceroid lipofuscinosis.
Drack AV; Miller JN; Pearce DA
J Child Neurol; 2013 Sep; 28(9):1112-6. PubMed ID: 23877479
[TBL] [Abstract][Full Text] [Related]
31. Myelin sheath decompaction, axon swelling, and functional loss during chronic secondary degeneration in rat optic nerve.
Payne SC; Bartlett CA; Harvey AR; Dunlop SA; Fitzgerald M
Invest Ophthalmol Vis Sci; 2012 Sep; 53(10):6093-101. PubMed ID: 22879411
[TBL] [Abstract][Full Text] [Related]
32. TNF-alpha-induced optic nerve degeneration and nuclear factor-kappaB p65.
Kitaoka Y; Kitaoka Y; Kwong JM; Ross-Cisneros FN; Wang J; Tsai RK; Sadun AA; Lam TT
Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1448-57. PubMed ID: 16565378
[TBL] [Abstract][Full Text] [Related]
33. Regional brain atrophy in mouse models of neuronal ceroid lipofuscinosis: a new rostrocaudal perspective.
Kühl TG; Dihanich S; Wong AM; Cooper JD
J Child Neurol; 2013 Sep; 28(9):1117-22. PubMed ID: 24014506
[TBL] [Abstract][Full Text] [Related]
34. Phenotypic characterization of a mouse model of juvenile neuronal ceroid lipofuscinosis.
Katz ML; Johnson GS; Tullis GE; Lei B
Neurobiol Dis; 2008 Feb; 29(2):242-53. PubMed ID: 17962032
[TBL] [Abstract][Full Text] [Related]
35. A knock-in reporter mouse model for Batten disease reveals predominant expression of Cln3 in visual, limbic and subcortical motor structures.
Ding SL; Tecedor L; Stein CS; Davidson BL
Neurobiol Dis; 2011 Feb; 41(2):237-48. PubMed ID: 20875858
[TBL] [Abstract][Full Text] [Related]
36. Using Patient-Specific Induced Pluripotent Stem Cells and Wild-Type Mice to Develop a Gene Augmentation-Based Strategy to Treat CLN3-Associated Retinal Degeneration.
Wiley LA; Burnight ER; Drack AV; Banach BB; Ochoa D; Cranston CM; Madumba RA; East JS; Mullins RF; Stone EM; Tucker BA
Hum Gene Ther; 2016 Oct; 27(10):835-846. PubMed ID: 27400765
[TBL] [Abstract][Full Text] [Related]
37. Altered Expression of Ganglioside Metabolizing Enzymes Results in GM3 Ganglioside Accumulation in Cerebellar Cells of a Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis.
Somogyi A; Petcherski A; Beckert B; Huebecker M; Priestman DA; Banning A; Cotman SL; Platt FM; Ruonala MO; Tikkanen R
Int J Mol Sci; 2018 Feb; 19(2):. PubMed ID: 29470438
[TBL] [Abstract][Full Text] [Related]
38. Intermediate levels of neuronal palmitoyl-protein Delta-9 desaturase in heterozygotes for murine Batten disease.
Narayan SB; Tan L; Bennett MJ
Mol Genet Metab; 2008 Jan; 93(1):89-91. PubMed ID: 17962056
[TBL] [Abstract][Full Text] [Related]
39. Glial cells are functionally impaired in juvenile neuronal ceroid lipofuscinosis and detrimental to neurons.
Parviainen L; Dihanich S; Anderson GW; Wong AM; Brooks HR; Abeti R; Rezaie P; Lalli G; Pope S; Heales SJ; Mitchison HM; Williams BP; Cooper JD
Acta Neuropathol Commun; 2017 Oct; 5(1):74. PubMed ID: 29041969
[TBL] [Abstract][Full Text] [Related]
40. Clinical and molecular characterization of non-syndromic retinal dystrophy due to c.175G>A mutation in ceroid lipofuscinosis neuronal 3 (CLN3).
Chen FK; Zhang X; Eintracht J; Zhang D; Arunachalam S; Thompson JA; Chelva E; Mallon D; Chen SC; McLaren T; Lamey T; De Roach J; McLenachan S
Doc Ophthalmol; 2019 Feb; 138(1):55-70. PubMed ID: 30446867
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
